Supplemental immune globulins in sepsis: a critical appraisal.

摘要: For 'the total population of patients with sepsis, sepsis syndrome or SIRS', the question whether intravenous immune globulin (IVIG) reduces mortality is neither proved nor disproved. subgroups 'postoperative a score more than 19' and 'endotoxaemic, early septic shock', significant reduction in by IVIG has been documented single, placebo-controlled, small trial each subgroup; subsequent studies are needed for confirmation. The incidence some severe infections defined 'patients at risk' 'operations lowered prophylaxis. Postoperative APACHE II-score identification high-risk cardiac surgery prone to SIRS may represent one approach optimize individual, therapy. Applying this concept treatment pilot study, administration IgG-IVIG IgGMA-IVIG yielded similar results.